Successful third-line chemotherapy for an adult with recurrent medulloblastoma

被引:0
|
作者
Filip Yves De Vos
Suzanne E. Kaal
Pieter Wesseling
Johanna M. Gijtenbeek
机构
[1] University Medical Centre Utrecht,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[3] Radboud University Nijmegen Medical Centre,Department of Pathology
[4] VU University Medical Center,Department of Pathology
[5] Radboud University Nijmegen Medical Centre,Department of Neuro
关键词
Adult medulloblastoma; Recurrent; Chemotherapy;
D O I
10.1007/s13691-013-0111-0
中图分类号
学科分类号
摘要
Medulloblastoma is a rare tumor in adults. There is no standard treatment, and extrapolation of treatment results from the pediatric population is flawed by differences in behavior of the tumor and in tolerance of treatment at different ages. In this case report, a patient with medulloblastoma and leptomeningeal metastases after standard chemoradiotherapy had rapid progressive disease after second-line temozolomide. However, partial response was achieved with third-line etoposide and carboplatin. Treatment choice should be based on toxicity management and the patient’s history to obtain higher efficacy, as in our case.
引用
收藏
页码:32 / 37
页数:5
相关论文
共 50 条
  • [21] Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity
    Manders, Dustin B.
    Kehoe, Siobhan M.
    Miller, David S.
    Lea, Jayanthi S.
    Richardson, Debra L.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (08): : 797 - 801
  • [22] Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy
    Hayashi, Masato
    Fujita, Takeshi
    Matsushita, Hisayuki
    KEIO JOURNAL OF MEDICINE, 2023, 72 (02): : 60 - 64
  • [23] CPT-11+CDDP in patients with metastatic and recurrent gastric cancer as a third-line chemotherapy.
    Yoshida, T
    Murakami, H
    Tsuburaya, A
    Kobayashi, O
    Sairenji, M
    Motohashi, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 364S - 364S
  • [24] Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi, Enrico
    Lamberti, Giuseppe
    Paccapelo, Alexandro
    Di Battista, Monica
    Genestreti, Giovenzio
    Minichillo, Santino
    Mura, Antonella
    Bartolini, Stefania
    Agati, Raffaele
    Brandes, Alba A.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 139 (02) : 383 - 388
  • [25] Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Enrico Franceschi
    Giuseppe Lamberti
    Alexandro Paccapelo
    Monica Di Battista
    Giovenzio Genestreti
    Santino Minichillo
    Antonella Mura
    Stefania Bartolini
    Raffaele Agati
    Alba A. Brandes
    Journal of Neuro-Oncology, 2018, 139 : 383 - 388
  • [26] Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
    Ready, Neal
    Farago, Anna F.
    de Braud, Filippo
    Atmaca, Akin
    Hellmann, Matthew D.
    Schneider, Jeffrey G.
    Spigel, David R.
    Moreno, Victor
    Chau, Ian
    Hann, Christine L.
    Eder, Joseph Paul
    Steele, Nicola L.
    Pieters, Anne
    Fairchild, Justin
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) : 237 - 244
  • [27] Third-line chemotherapy for small cell lung cancer (SCLC)
    de Jong, W
    ten Hacken, N
    Groan, H
    LUNG CANCER, 2005, 49 : S317 - S318
  • [28] Second-line and third-line chemotherapy for lung cancer: Use and cost
    Ramsey, Scott D.
    Martins, Renato G.
    Blough, David K.
    Tock, Lauri S.
    Lubeck, Deborah
    Reyes, Carolina M.
    AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (05): : 297 - 306
  • [29] The role of third-line chemotherapy in recurrent or metastatic gastric cancer A cohort study with propensity score matching analysis
    Choi, Yong Won
    Ahn, Mi Sun
    Jeong, Geum Sook
    Lee, Hyun Woo
    Jeong, Seong Hyun
    Kang, Seok Yun
    Park, Joon Seong
    Choi, Jin-Hyuk
    Sheen, Seung Soo
    MEDICINE, 2018, 97 (39)
  • [30] Successful establishment of third-line antiretroviral therapy in Malawi: lessons learned
    Heller, T.
    Ganesh, P.
    Gumulira, J.
    Nkhoma, L.
    Chipingu, C.
    Kanyama, C.
    Kalua, T.
    Nyrienda, R.
    Phiri, S.
    Schooley, A.
    PUBLIC HEALTH ACTION, 2019, 9 (04): : 169 - 173